Seelos Therapeutics, Inc.
SEEL · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -35.1% | -11.3% | 60.8% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -100.8% | 97.4% | 97.7% | 96.6% |
| EBITDA | $0 | -$0 | -$0 | $0 |
| % Margin | 464.9% | -453.5% | -829.9% | 2,599.5% |
| Net Income | $0 | -$0 | -$0 | $0 |
| % Margin | 454.8% | -460.1% | -835.1% | 2,585.7% |
| EPS Diluted | 0.12 | -0.72 | -1.47 | 2.13 |
| % Growth | 116.7% | 51% | -169% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |